

# Recommended Treatments: Hepatitis C Virus (HCV) Genotypes 3-6

Based on AASLD recommendations (09/21/2017)

All recommended treatments are listed alphabetically in tables and are evidence level "I, A" unless noted after # wks  
Alternative treatments are footnoted (only those with I,A evidence are provided)

GENOTYPE 3	# pill(s) taken once/day	No cirrhosis		Cirrhosis	
		Treatment naïve	<sup>1</sup> Peg-IFN/RBV Exp.	Treatment naïve	<sup>1</sup> Peg-IFN/RBV Exp.
<b>Epclusa</b> sofosbuvir/velpatasvir	1 pill	12wks	12wks	12wks	+ VOX; 12wks (IIb,B) (VOSEVI)
<b>Maviret</b> glecaprevir/pibrentasvir	3 pills	8wks	--	12wks	--
<b>Zepatier</b> elbasvir/grazoprevir	1 pill	--	--	--	+ SOF; 12wks (I,B)
Alternative treatments (I,A)		See footnote 2	See footnote 2	--	--

GENOTYPE 4	# pill(s) taken once/day	No cirrhosis		Cirrhosis	
		Treatment naïve	<sup>1</sup> Peg-IFN/RBV Exp.	Treatment naïve	<sup>1</sup> Peg-IFN/RBV Exp.
<b>Epclusa</b> (I,A) sofosbuvir/velpatasvir	1 pill	12wks	12wks	12wks	12wks
<b>Harvoni</b> ledipasvir/sofosbuvir	1 pill	12wks (IIa,B)	12wks (IIa,B)	12wks (IIa,B)	--
<b>Maviret</b> glecaprevir/pibrentasvir	3 pills	8wks	8wks (I,B)	12wks (I,B)	12wks (IIa,B)
<b>Zepatier</b> (IIa,B) elbasvir/grazoprevir	1 pill	12wks (IIa,B)	12wks (IIa,B) (if virologic relapsed)	12wks (IIa,B)	12wks (IIa,B) (if virologic relapsed)
Alternative treatments (I,A)		See footnote 3	See footnote 3	See footnote 3	See footnote 3

GENOTYPE 5-6	# pill(s) taken once/day	No cirrhosis		Cirrhosis	
		Treatment naïve	<sup>1</sup> Peg-IFN/RBV Exp.	Treatment naïve	<sup>1</sup> Peg-IFN/RBV Exp.
<b>Epclusa</b> sofosbuvir/velpatasvir	1 pill	12wks (I,B)	12wks (IIa,B)	12wks (I,B)	12wks (IIa,B)
<b>Harvoni</b> ledipasvir/sofosbuvir	1 pill	12wks (IIa,B)	12wks (IIa,B)	12wks (IIa,B)	12wks (IIa,B)
<b>Maviret</b> glecaprevir/pibrentasvir	3 pills	8wks	8wks (IIa,B)	12wks	12wks (I,B)

**Abbreviations:** Wks weeks; Peg-IFN pegylated interferon; RBV ribavirin; Exp Experienced; SOF sofosbuvir; VOX voxilaprevir  
**Evidence ratings:** I,A = Class I Level A, etc. (for all evidence levels see [www.hcvguidelines.org](http://www.hcvguidelines.org))

<sup>1</sup> See [www.hcvguidelines.org](http://www.hcvguidelines.org) for patients with treatment experiences that included: NS3 protease inhibitor +Peg-IFN/RBV Non-NS5A Inhibitor sofosbuvir-containing regimen; and NS5A inhibitor DAA-experienced.

<sup>2</sup> Alternative treatment (I,A): daclatasvir + sofosbuvir; 12 wks

<sup>3</sup> Alternative treatment (I,A): paritaprevir/ritonavir/ombitasvir + RBV; 12 wks

